Back to results
US 2022/0064321 A1Published application
Anti-cd20 antibody
AssigneeBeijing Mabworks Biotech Co., Ltd.
InventorsFeng LI, Boyan ZHANG, Pei YE
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeBeijing Mabworks Biotech Co., Ltd.
InventorsFeng LI, Boyan ZHANG, Pei YE
Estimating the term…
The present invention relates to a humanized anti-CD20 antibody that comprises an antigen binding site containing heavy and light chain of obinutuzumab (GAZYVA®), and N-linked oligosaccharides that are attached to the Fc region of the antibody, wherein the N-linked oligosaccharides are not bisected by N-acetylglucosamine. The antibody of the present invention comprises fucose glycotype in an amount of no more than 10% of the total N-glycans that are attached to the Fc region of the antibody. The anti-CD20 of the present invention has antibody dependent cell-mediated cytotoxicity (ADCC) about 2 times stronger than that of GAZYVA® and about 50 to 100 times stronger than that of RITUXAN®. The anti-CD20 antibodies are effective for treating CD20 expressing cancer, such as non-Hodgkin's lymphoma, B cell lymphoma, chronic lymphocytic leukemia, or follicular lymphoma.
A method for treating cancer, comprising administering an effective amount of humanized anti-CD20 antibodies to a subject in need thereof, wherein said humanized anti-CD20 antibodies comprises:
A method for treating an autoimmune disease, comprising administering an effective amount of humanized anti-CD20 antibodies to a subject in need thereof, wherein said humanized anti-CD20 antibodies comprising:
Dependencies are inferred from the claim text.